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Abstract  
The associations of individual dietary fatty acids with prostate cancer risk have not been 
examined comprehensively. We examined the prospective association of individual dietary 
fatty acids with prostate cancer risk overall, by tumor subtypes, and prostate cancer death. 
142,239 men from the European Prospective Investigation into Cancer and Nutrition who 
were free from cancer at recruitment were included. Dietary intakes of individual fatty acids 
were estimated using center-specific validated dietary questionnaires at baseline and 
calibrated with 24-hour recalls. Multivariable Cox regression models were used to estimate 
hazard ratios (HRs) and 95% confidence intervals (CIs). After an average follow-up of 13.9 
years, 7,036 prostate cancer cases and 936 prostate cancer deaths were ascertained. Intakes of 
individual fatty acids were not related to overall prostate cancer risk. There was evidence of 
heterogeneity in the association of some short chain saturated fatty acids with prostate cancer 
risk by tumor stage (Pheterogeneity<0.015), with a positive association with risk of advanced 
stage disease for butyric acid (4:0; HR1SD=1.08; 95%CI=1.01-1.15; P-trend=0.026). There 
were no associations with fatal prostate cancer, with the exception of a slightly higher risk for 
those who consumed more eicosenoic acid (22:1n-9c; HR1SD=1.05; 1.00-1.11; P-
trend=0.048) and eicosapentaenoic acid (20:5n-3c; HR1SD=1.07; 1.00-1.14; P-trend=0.045). 
There was no evidence that dietary intakes of individual fatty acids were associated with 
overall prostate cancer risk. However, a higher intake of butyric acid might be associated 
with a higher risk of advanced, whereas intakes of eicosenoic and eicosapentaenoic acids 
might be positively associated with fatal prostate cancer risk. 
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Introduction  
Prostate cancer is the most frequently diagnosed cancer in men in Europe 1, but the well-
established risk factors age, ethnicity, genetic factors and family history of the disease are not 
modifiable 2, 3. There is also evidence that circulating insulin-like growth factor-I (IGF-I) is 
related to higher overall prostate cancer risk 4, and obesity has been associated with a higher 
risk of aggressive disease 5. Moreover, the wide international variation in prostate cancer 
incidence and the changing rates observed in migrant studies suggest that environmental and 
lifestyle factors, such as dietary factors, are possible risk factors for the disease 6. However, 
some of this international variation is due to differences between countries in prostate-
specific antigen (PSA) testing, which has especially increased the diagnosis of nonaggressive 
tumors 1; therefore to provide more clarity on prostate cancer etiology it is important that 
analytical studies characterize prostate cancer by stage, grade and fatality of the disease. 
The possible role of total and specific types of dietary fats in relation to prostate cancer 
development and progression has attracted much interest 7, 8. The latest meta-analysis from 
the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) 
stated that the evidence was limited and no conclusion could be reached on whether 
consumption of total fat, saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), 
or polyunsaturated fatty acids (PUFAs) is associated with overall prostate cancer risk or with 
risk for ‘advanced/high grade’ prostate cancer 2, 9. However, this meta-analysis did not 
differentiate between stage and grade of the disease because of the small number of available 
studies with data on both these outcomes, and associations with prostate cancer death were 
not available. Moreover, recent studies have shown that individual fatty acids may confer 
heterogeneous health effects 10-12, which might explain the current inconclusive results on the 
role of dietary fat on prostate cancer.  
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The aim of this study was to examine the association of intakes of individual dietary fatty 
acids with the risk of prostate cancer, and to examine whether any associations differ by 
tumor grade, stage, or for death from prostate cancer in the European Prospective 
Investigation into Cancer and Nutrition (EPIC). 
Material and methods 
Subjects and study design 
EPIC includes 153,457 men recruited between 1992 and 2000 from 19 centers, most aged 35-
70 years, in 19 centers in eight European countries (Denmark, Germany, Greece, Italy, 
Netherlands, Spain, Sweden and United Kingdom (UK)) (more details in Supplementary 
Methods). The details of the study design used in the EPIC study have been described 
elsewhere 13. Men were not eligible for this analysis if they were diagnosed with cancer 
(except non-melanoma skin cancer) before recruitment (n = 3,972), if they had missing dates 
of prostate cancer diagnosis (n = 14) or follow-up (n = 1,433), or if they were aged <20 years 
at recruitment (n = 2). Men were also excluded if they had no non-dietary or dietary data, or 
if they had an extreme energy intake in relation to estimated requirement (top and bottom 1%, 
n = 5,766) 14. Complete data on diet and follow-up for prostate cancer were available for 
142,239 men (Supplementary Figure 1). 
Assessment of dietary intake and other predictor variables 
At baseline, information was collected on lifestyle, health status, socio-demographic 
characteristics, anthropometry and medical history 13. Dietary intake during the year before 
enrolment was measured by country- or center-specific validated food frequency 
questionnaires (FFQs) or diet histories, as previously described 13, 15. To correct for any 
systematic under- or overestimation of dietary intake across the participating centers, dietary 
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intakes from the questionnaires were calibrated using a standardized, computer-based, 24-h 
dietary recall method in an 8% random sample of the whole EPIC cohort.  
In order to estimate the intakes of individual fatty acids, the EPIC Nutrient Database (ENDB) 
was matched with the National Nutrient Database for Standard Reference of the United States 
(NNDSR; developed at the USDA) 16. The fatty acid intakes reported in this manuscript were 
obtained through this extra USDA matching (more details in Supplementary Methods). Due 
to the very small amounts of some individual fatty acids, we only included those with a mean 
total intake of at least 0.05 grams/day in these analyses, with the exception of 
docosapentaenoic acid (22:5n-3c), which was included due to its previously suggested role in 
prostate cancer risk 12. Fatty acids were presented and analyzed as grams per 1000 kcal/day in 
order to control for confounding by total energy intake 17. Short chain fatty acids were 
strongly correlated with each other (Supplementary table 2A), probably because of their 
shared food sources 18; therefore, in addition to analyzing short chain SFAs individually, they 
were also combined together in groups as 4:0-10:0 and 12:0-14:0 10. 
Ascertainment of prostate cancer 
The main source of information on cancer incidence, tumor subtypes and vital status was 
population-based cancer and mortality registries. In Germany and Greece follow-up was 
based on a combination of methods, including health insurance records, cancer and pathology 
registries, as well as active follow-up through participants or relatives; self-reported incident 
cancers were verified through medical records. Follow-up began at the date of recruitment 
and was censored at the date of last known contact, or at the date of diagnosis of cancer, 
death, emigration or the end of the follow-up period, whichever came first. Prostate cancer (n 
= 7,036) was defined as code C61 in the 10th Revision of the International Statistical 
Classification of Diseases, Injuries and Causes of Death (ICD) 19. 
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Grade (based on Gleason sum) was classified as low-intermediate (Gleason sum of < 8, or 
grade coded as well, moderately, or poorly differentiated; n = 3,757) or high (Gleason sum of 
≥ 8, or grade coded as undifferentiated; n = 726) grade. Information on stage was based on 
tumor-node-metastasis (TNM) staging code. Localized stage included those confined within 
the prostate and with no metastases at diagnosis (TNM staging score of ≤ T2 and N0/Nx and 
M0, or stage coded in the recruitment center as localized; n = 2,641). Advanced cases 
included tumors that had spread beyond the prostate at diagnosis (T3-T4 and/or N1-N3 and/or 
M1, and/or stage coded in the recruitment center as metastatic; n = 1,389). Fatal cases were 
those who died of prostate cancer (n = 936). 
Statistical analysis 
Baseline characteristics of the study population were calculated across fifths of total SFAs, 
MUFAs and PUFAs intake in grams/1000 kcal and presented as means with standard 
deviations (SDs) for continuous variables or percentages for categorical variables. Pearson 
correlations between intakes of individual SFAs, MUFAs and PUFAs were calculated.  
Each individual fatty acid was divided into fifths of intake in grams/1000 kcal/day based on 
the distribution in the EPIC cohort and also modeled as continuous variables per SD higher 
intake.  
Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox 
proportional hazards models using attained age as the underlying time variable. The date of 
last follow-up ranged from January 2011 in Germany to October 2013 in Spain. All analyses 
were stratified by center and age (<50, 50-54.9, 55-59.9, 60-64.9, 65-69.9, and ≥70 years) at 
recruitment. To check for violation of the proportional hazards assumption we used time-
varying covariates and Schoenfeld residuals, which did not indicate violation from the 
proportional hazards assumption. Tests for linear trend were performed using continuous 
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values for dietary fatty acids, with increments based on one SD increase. All models were 
adjusted for educational level (no degree or equivalent, degree or equivalent, unknown), 
smoking status (never, former, current, unknown), marital status (married or cohabiting, not 
married or cohabiting, unknown), diabetes (no, yes, unknown), physical activity (inactive, 
moderately inactive, moderately active, active, unknown 20), height (<170, 170–174, 175–
179, ≥ 180 cm, unknown), BMI (<22.5, 22.5–24.9, 25–29.9, ≥ 30 kg/m2, unknown), and total 
energy intake (fifths). Participants with missing values were assigned an “unknown” 
category; <3% of values were missing for each covariate, with the exception of marital status, 
for which 30% of values were missing. 
Tests for heterogeneity of trends for histological grade (low-intermediate or high), tumor 
stage (localized or advanced), and time between blood collection and diagnosis (<5 years, ≥5 
years)] were performed. For this, we fitted separate models for each subgroup assuming 
independence of the HRs using a method analogous to competing risks, and compared the 
risk coefficients and standard errors in the subgroups of interest after excluding cases of 
unknown grade or stage 21.  
All analyses were performed using Stata version 14.1 (Stata Corporation, College Station, 
TX, USA), all tests of significance were two-sided, and a P-value less than 0.05 was 
considered statistically significant. Conventional p-values are shown but the results were 
interpreted in the light of the number of tests performed.  
Results 
A total of 7,036 men were diagnosed with prostate cancer after an average follow-up time of 
13.9 years. The median age at prostate cancer diagnosis was 68 years (range, 41-95 years). 
Table 1 shows the characteristics of the study participants at baseline. Some baseline 
characteristics varied by fatty acids consumption. For example, men in the highest fifth of 
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SFAs intake were more likely to have an education degree and have a higher total energy 
intake. Men in the highest fifths of MUFAs and PUFAs intake were more likely to be 
younger at recruitment and older at prostate cancer diagnosis.  
Palmitic acid (16:0), oleic acid (18:1n-9c) and linoleic acid (18:2n-6c) were the largest 
contributors to total SFAs, MUFAs and PUFAs intake, respectively (Supplementary table 
1). Butyric acid (4:0), caproic acid (6:0), caprylic acid (8:0) and capric acid (10:0) were 
strongly correlated with each other (correlation coefficients ranged from 0.840 to 0.972). 
There was also a strong correlation between palmitic acid (16:0) and stearic acid (18:0) 
(correlation coefficient 0.814, Supplementary Table 2A). Although individual MUFAs were 
correlated, these correlations were not very strong (Supplementary Table 2B). The PUFAs 
eicosapentaenoic acid (20:5n-3c), docosapentaenoic acid (22:5n-3c) and docosahexaenoic 
acid (22:6n-3c) were also strongly correlated (correlation coefficients ranged from 0.872 to 
0.968, Supplementary Table 2C) 
The associations of intakes of individual SFAs, MUFAs and PUFAs with risk for overall 
prostate cancer, prostate cancer subdivided by grade and stage of disease, and for prostate 
cancer death, using both the observed and calibrated intakes, are shown in Tables 2 
(Supplementary Table 3 for observed intakes), 3 (Supplementary Table 4 for observed 
intakes), and 4 (Supplementary Table 5 for observed intakes), respectively. Results for 
observed and calibrated intakes were similar in direction; therefore, from here on we will 
only report calibrated results.  
Intakes of individual SFAs, MUFAs and PUFAs were not related to overall prostate cancer 
risk (Supplementary table 6 and Tables 2, 3 and 4). Removing BMI as a covariate in the 
model has no impact on any of the results. There was no evidence of heterogeneity in 
separate analyses by grade (Tables 2, 3 and 4). We found evidence of heterogeneity in the 
association of some SFAs [butyric acid (4:0), caproic acid (6:0), 4:0-10:0 combined and 12:0-
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14:0 combined] with prostate cancer risk by tumor stage (Pheterogeneity for all < 0.03; Table 2), 
with a positive association with risk of advanced stage disease for butyric acid (4:0; HR1SD in 
calibrated intake = 1.08; 1.01-1.15; P-trend=0.026), and no significant associations with localized 
disease. There was also evidence of heterogeneity by tumor stage (Pheterogeneity = 0.021) in the 
association between arachidonic acid (20:4n-6c) with prostate cancer risk, with a higher 
intake of this PUFA being weakly associated with a lower risk of advanced disease (HR1SD in 
calibrated intake = 0.91, 0.82-1.01; P-trend=0.072; Table 4). 
We observed no associations between intakes of individual dietary fatty acids and prostate 
cancer death, with the exception of a small increased risk for those with a higher intake of 
eicosenoic acid (22:1n-9c; HR1SD in calibrated intake = 1.05; 95% CI 1.00-1.11; P-trend=0.048; 
Table 3) and eicosapentaenoic acid (20:5n-3c; HR1SD in calibrated intake = 1.07; 95% CI 1.00-1.14; 
P-trend=0.045; Table 4). 
Although there was some evidence of heterogeneity for the association of some long-chain 
SFAs with total prostate cancer risk when subdivided by time between recruitment and 
diagnosis (<5 years, ≥5 years; Supplementary Table 7), the associations at each of the 
follow-up times were not statistically significant. There was no evidence of heterogeneity for 
the rest of individual fatty acids by follow-up time.  
 
Discussion 
In this large prospective study, intakes of individual fatty acids were not associated with 
overall prostate cancer risk. However, a higher intake of butyric acid was positively 
associated with risk for advanced stage prostate cancer. There was also a small increased risk 
of fatal prostate cancer risk with higher intakes of eicosenoic acid and eicosapentaenoic acid.  
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The possible association between fat intake (total fat and specific fatty acids) with prostate 
cancer risk and/or progression has generated considerable debate. Animal and cell studies 
have shown that dietary fat can promote metastasis 22-24. Several mechanisms that may 
underpin this association have been proposed. These include a positive association of total fat 
intake with IGF-I 25 and androgen 26 concentrations and, based on experiments in mice, a 
possible role in the activation of the IGF-Akt pathway and the proliferation of prostatic 
intraepithelial neoplasia (PIN) epithelial cells 23. Nevertheless, data from prospective studies 
are inconclusive 2. There are various differences between prospective studies that could 
account for the inconclusive findings, such as that most studies have combined grade and 
stage of the disease, and that the type of fatty acid rather than total amount may play a role in 
prostate cancer development and/or progression. 
Our finding of an increased risk of advanced prostate cancer associated with higher butyric 
acid (4:0), caproic acid (6:0), and 4:0-10:0 combined intakes is difficult to put into context, as 
other prospective studies have not examined these associations. A previous survival analyses 
among Swedish men initially diagnosed with localized prostate cancer found that a higher 
intake of short chain fatty acids (4:0-10:0) may increase risk of prostate cancer death 27; 
myristic acid (14:0) was also related with worse prostate cancer survival in this study, but we 
did not find an association of this SFA with prostate cancer risk. A prospective study in 
Japanese men also found a positive association between myristic and palmitic acid and 
prostate cancer risk 28. Dairy products are the main dietary source of short chain fatty acids 18, 
which might be involved in prostate cancer etiology 2. Therefore, it is also possible that the 
observed associations are driven by other compounds present in dairy products, such as 
protein or calcium 29. However, when we further adjusted the multivariable-adjusted models 
for protein or calcium from dairy products, the significant association between butyric acid 
and advanced prostate cancer risk was maintained and was even a bit stronger (protein 
 
 
15 
 
adjustment, HR1SD in calibrated intake = 1.09; 1.02-1.16; P-trend=0.016; calcium adjustment, HR1SD 
in calibrated intake = 1.09; 1.01-1.16; P-trend=0.020). Moreover, butter is particularly high in 
butyric acid and it is also a good source of phytanic acid, which has been related to prostate 
cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 30, a cohort of 
Finnish male smokers. Phytanic acid is also high in fish, and as discussed below, we have 
also found a weak association between eicosapentaenoic acid and death from prostate cancer. 
However, circulating phytanic acid concentrations were not significantly associated with 
prostate cancer risk in the EPIC cohort 31. 
A higher intake of arachidonic acid (20:4n-6c) was weakly associated with a lower risk of 
advanced disease, which is consistent with a previous individual participant meta-analysis of 
prospective studies on circulating fatty acids that found an inverse association with 
aggressive prostate cancer 12. However, previous prospective studies have found no 
association between dietary arachidonic acid and prostate cancer risk 32, 33. The possible 
mechanisms whereby arachidonic acid may inhibit prostate cancer progression are unknown, 
because previous experimental studies have suggested that the arachidonic acid pathway may 
be implicated in prostate cancer development and progression through its involvement in 
inflammation and cell growth 34. Further research is therefore needed before conclusions on 
risk can be drawn.  
We also found some evidence that both eicosenoic (22:1n-9c) and eicosapentaenoic acid 
(20:5n-3c) may be associated with a higher risk of death from prostate cancer. To the best of 
our knowledge, no previous prospective study has looked at the association between 
eicosenoic acid and prostate cancer risk, but this fatty acid is often found in similar foods as 
eicosapentaenoic acid (e.g. fish, and nuts and seeds) 35. Circulating eicosapentaenoic acid 
concentrations have been associated with a higher risk of total prostate cancer in a pooled 
analysis of prospective studies 12 and dietary intake of eicosapentaenoic acid was associated 
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with a higher risk of advanced and fatal prostate cancer in the NIH-AARP study 36. However, 
results from the Health Professionals Follow-Up Study showed that a higher intake of 
eicosapentaenoic acid was associated with a lower risk of total and advanced prostate cancer 
32.  
It was suggested in 1993 that α-linolenic acid was positively associated with advanced 
prostate cancer 37. However, our results, the latest meta-analysis from the WCRF/AIRC 2, and 
findings from a pooling study on circulating fatty acids 12 do not support the hypothesis that 
higher intake of α-linolenic acid increases the risk of prostate cancer. Previous prospective 
studies have also suggested that docosapentaenoic acid (22:5n-3c) is involved in prostate 
cancer development 12, but we found no association between this fatty acid and prostate 
cancer risk. A Mendelian randomization analysis of data from up to 22,721 prostate cancer 
cases in the PRACTICAL consortia found no strong evidence for an association between 
several PUFAs, such as arachidonic acid, eicosapentaenoic acid, and docosapentaenoic acid, 
and overall and advanced prostate cancer risk 38. 
This study has some strengths and limitations that should be considered. The major strengths 
include the prospective design and the large sample size, which allowed investigation of fatty 
acids by stage and grade of prostate cancer tumors and death from prostate cancer. This study 
also had reliable identification of prostate cancer cases through cancer registries and/or 
verified medical records. The Gleason grade was based on data available from biopsies and 
surgical pathology, although there may be some misclassification because of changes in 
grading over time. The dietary questionnaires in all EPIC centers were validated and dietary 
intakes were calibrated using measures from a standardized 24-h diet recall method to correct 
for over and under-estimation of dietary intake 39.  
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A limitation of the current study was the use of dietary fatty acids intake obtained from  
assessment questionnaires only at recruitment, which are subject to random measurement 
error and changes over time, and this would likely lead to an underestimation of true 
associations. Although we adjusted for multiple covariates, potential unmeasured and residual 
confounding cannot be excluded, including having a PSA test which was not available in our 
cohort. In addition, some of the associations observed might be due to chance because of the 
number of tests performed, and if we correct for multiple testing there would not be any 
significant results. Moreover, because some dietary fatty acids are highly correlated, it is 
difficult to disentangle their independent associations with prostate cancer. It is also unclear 
whether the risk differences observed in our study are attributable to the individual fatty acids 
or if they might be driven by other compound(s) in their food sources. Finally the fatty acids 
food sources may vary across the European countries included in this study, for example, the 
primary food that contributes to oleic acid intake in the south of Europe is olive oil, whereas 
in some populations in the north of Europe the primary food source is meat 40. 
In conclusion, intakes of individual fatty acids were not related to overall prostate cancer risk. 
However, our results suggest that higher intake of butyric acid may be associated with an 
increased risk of advanced prostate cancer. We also found a suggestive increased risk of fatal 
prostate cancer risk with higher intakes of eicosenoic acid and eicosapentaenoic acid. Further 
prospective studies and meta-analyses are required to better understand the role of individual 
dietary fatty acids in prostate cancer development and progression. 
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Table 1. Baseline characteristics of 142,239 men in EPIC (1992-2013) according to observed SFAs, MUFAs and PUFAs intakes. 
  Fifths of observed SFAs intake   Fifths of observed MUFAs intake   Fifths of observed PUFAs intake 
  1 3 5   1 3 5   1 3 5 
No. of men 28448 28448 28447 
 
28448 28448 28447 
 
28448 28448 28447 
Age at recruitment1, y 52.2 (9.7) 51.7 (10.3) 51.1 (10.3) 
 
52.8 (10.6) 51.8 (9.8) 50.6 (10.5) 
 
52.3 (8.5) 51.7 (10.1) 51.0 (11.4) 
Age at diagnosis1, y  67.8 (6.4) 68.1 (6.8) 67.5 (6.9) 
 
68.7 (6.8) 68.0 (6.5) 66.9 (6.7) 
 
67.1 (6.2) 67.8 (6.6) 68.5 (7.0) 
Smoking, n (%) 
           Never  8990 (31.6) 9475 (33.3) 9526 (33.5) 
 
9958 (35.0) 9713 (34.1) 8175 (28.7) 
 
7794 (27.4) 9721 (34.2) 10262 (36.1) 
Former  10650 (37.4) 10266 (36.1) 9838 (34.6) 
 
11130 (39.1) 10299 (36.2) 9400 (33.0) 
 
10983 (38.6) 10481 (36.8) 9347 (32.9) 
Current  8479 (29.8) 8281 (29.1) 8704 (30.6) 
 
6979 (24.5) 8137 (28.6) 10193 (35.8) 
 
9375 (33.0) 7892 (27.7) 8324 (29.3) 
Educational level, n (%) 
           No degree 20722 (72.8) 20560 (72.3) 18919 (66.5) 
 
18064 (63.5) 19806 (69.6) 22702 (79.8) 
 
21226 (74.6) 19770 (69.5) 19954 (70.1) 
Degree 6638 (23.3) 7156 (25.2) 8918 (31.3) 
 
8724 (30.7) 7996 (28.1) 5552 (19.5) 
 
6887 (24.2) 8014 (28.2) 7139 (25.1) 
Physical activity, n (%) 
           Inactive 5527 (19.4) 5134 (18.0) 5539 (19.5) 
 
5366 (18.9) 4745 (16.7) 6816 (24.0) 
 
5002 (17.6) 5221 (18.4) 5861 (20.6) 
Moderately inactive 8502 (29.9) 8721 (30.7) 8854 (31.1) 
 
8426 (29.6) 8770 (30.8) 8782 (30.9) 
 
9033 (31.8) 8618 (30.3) 8285 (29.1) 
Moderately active 6950 (24.4) 6793 (23.9) 6958 (24.5) 
 
6773 (23.8) 6906 (24.3) 7013 (24.7) 
 
6943 (24.4) 7004 (24.6) 6992 (24.6) 
Active 7190 (25.3) 7088 (24.9) 6320 (22.2) 
 
7297 (25.7) 7271 (25.6) 5570 (19.6) 
 
7272 (25.6) 6870 (24.1) 6516 (22.9) 
Diabetes at baseline, n (%) 
           No 26578 (93.4) 26848 (94.4) 26869 (94.5) 
 
26618 (93.6) 26937 (94.7) 26610 (93.5) 
 
27048 (95.1) 26715 (93.9) 26680 (93.8) 
Yes 1203 (4.2) 923 (3.2) 1064 (3.7) 
 
1024 (3.6) 864 (3.0) 1459 (5.1) 
 
981 (3.4) 1104 (3.9) 961 (3.4) 
Marital status, n (%) 
           Married 11222 (39.4) 16441 (57.8) 19193 (67.5) 
 
14234 (50.0) 15587 (54.8) 18378 (64.6) 
 
16023 (56.3) 15925 (56.0) 15389 (54.1) 
Not married 2944 (10.3) 3624 (12.7) 4983 (17.5) 
 
4210 (14.8) 3707 (13.0) 3117 (11.0) 
 
3084 (10.8) 3785 (13.3) 4395 (15.4) 
Height1, cm 173.1 (7.4) 175.0 (7.3) 175.8 (7.1) 
 
175.4 (7.0) 175.5 (7.2) 172.2 (7.5) 
 
173.5 (7.3) 175.2 (7.2) 174.9 (7.5) 
BMI1, kg/m2 26.8 (3.7) 26.4 (3.6) 26.3 (3.7) 
 
26.3 (3.7) 26.2 (3.5) 27.3 (3.8) 
 
26.7 (3.6) 26.5 (3.6) 26.2 (3.8) 
Total energy intake1, Kcal/d 2,289 (641) 2,426 (650) 2,508 (701)   2,232 (623) 2,442 (641) 2,500 (703)   2,431 (679) 2,391 (648) 2,438 (676) 
Percentages do not match due to missing data. Fifths calculated from g/1000 kcal of each fatty acid. 
1 Values are means (SD). 
Abbreviations: BMI, body mass index; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids. 
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Table 2. Multivariable-adjusted hazard ratios (95 % CI) for prostate cancer per 1-SD increase of 
total fat and individual saturated fatty acids intake in 142,239 men in EPIC (1992-2013). 
    Calibrated 
  No. cases HR (95 % CI)1 P trend2 P het3 
Total Fat 
    Total prostate cancer 7036 0.99 (0.96 - 1.02) 0.389 
 Grade 
      Low 3757 0.95 (0.91 - 1.00) 0.038 
   High 726 1.04 (0.95 - 1.14) 0.419 0.084 
Stage 
      Localized 2641 0.98 (0.93 - 1.04) 0.544 
   Advanced 1389 1.01 (0.95 - 1.08) 0.708 0.392 
Fatal prostate cancer 936 1.00 (0.92 - 1.08) 0.965 
 Total SFAs 
    Total prostate cancer 7036 1.00 (0.96 - 1.03) 0.850 
 Grade 
      Low 3757 0.96 (0.92 - 1.01) 0.144 
   High 726 1.07 (0.96 - 1.19) 0.234 0.041 
Stage 
      Localized 2641 0.97 (0.91 - 1.02) 0.239 
   Advanced 1389 1.05 (0.97 - 1.13) 0.257 0.052 
Fatal prostate cancer 936 1.02 (0.92 - 1.12) 0.723 
 Butyric acid (4:0) 
    Total prostate cancer 7036 1.01 (0.98 - 1.04) 0.496 
 Grade 
      Low 3757 0.99 (0.95 - 1.03) 0.724 
   High 726 1.07 (0.97 - 1.17) 0.162 0.035 
Stage 
      Localized 2641 0.96 (0.92 - 1.01) 0.135 
   Advanced 1389 1.08 (1.01 - 1.15) 0.026 0.004 
Fatal prostate cancer 936 1.02 (0.94 - 1.12) 0.599 
 Caproic acid (6:0) 
    Total prostate cancer 7036 1.00 (0.97 - 1.04) 0.819 
 Grade 
      Low 3757 0.98 (0.94 - 1.02) 0.380 
   High 726 1.06 (0.97 - 1.16) 0.198 0.034 
Stage 
      Localized 2641 0.96 (0.91 - 1.00) 0.071 
   Advanced 1389 1.06 (1.00 - 1.13) 0.053 0.006 
Fatal prostate cancer 936 1.03 (0.95 - 1.12) 0.476 
 Caprylic acid (8:0) 
    Total prostate cancer 7036 1.00 (0.97 - 1.03) 0.937 
 Grade 
      Low 3757 0.97 (0.93 - 1.01) 0.156 
   High 726 1.04 (0.95 - 1.14) 0.394 0.068 
Stage 
      Localized 2641 0.95 (0.91 - 1.00) 0.042 
   Advanced 1389 1.05 (0.99 - 1.12) 0.122 0.013 
Fatal prostate cancer 936 1.05 (0.97 - 1.13) 0.272 
 Capric acid (10:0) 
    Total prostate cancer 7036 1.01 (0.97 - 1.04) 0.775 
 Grade 
      Low 3757 0.98 (0.94 - 1.03) 0.397 
   High 726 1.06 (0.95 - 1.17) 0.317 0.072 
Stage 
      Localized 2641 0.96 (0.90 - 1.01) 0.116 
   Advanced 1389 1.06 (0.99 - 1.14) 0.093 0.023 
Fatal prostate cancer 936 1.04 (0.94 - 1.14) 0.481 
 Lauric acid (12:0) 
    Total prostate cancer 7036 1.00 (0.97 - 1.04) 0.791 
 Grade 
      Low 3757 0.98 (0.93 - 1.02) 0.333 
   High 726 1.07 (0.97 - 1.19) 0.182 0.102 
Stage 
      Localized 2641 0.96 (0.91 - 1.01) 0.153 
   Advanced 1389 1.07 (0.99 - 1.14) 0.079 0.078 
Fatal prostate cancer 936 1.06 (0.96 - 1.17) 0.253 
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Myristic acid (14:0) 
    Total prostate cancer 7036 1.00 (0.97 - 1.04) 0.916 
 Grade 
      Low 3757 0.97 (0.93 - 1.02) 0.208 
   High 726 1.06 (0.96 - 1.17) 0.265 0.028 
Stage 
      Localized 2641 0.96 (0.91 - 1.01) 0.113 
   Advanced 1389 1.06 (0.98 - 1.14) 0.129 0.013 
Fatal prostate cancer 936 1.04 (0.95 - 1.14) 0.426 
 Pentadecanoic acid (15:0) 
    Total prostate cancer 7036 0.98 (0.94 - 1.01) 0.152 
 Grade 
      Low 3757 0.99 (0.94 - 1.04) 0.618 
   High 726 0.93 (0.84 - 1.03) 0.146 0.427 
Stage 
      Localized 2641 0.96 (0.91 - 1.02) 0.212 
   Advanced 1389 0.97 (0.91 - 1.04) 0.430 0.511 
Fatal prostate cancer 936 0.97 (0.89 - 1.05) 0.410 
 Palmitic acid (16:0) 
    Total prostate cancer 7036 0.99 (0.95 - 1.03) 0.627 
 Grade 
      Low 3757 0.96 (0.91 - 1.01) 0.104 
   High 726 1.06 (0.95 - 1.19) 0.282 0.064 
Stage 
      Localized 2641 0.97 (0.91 - 1.03) 0.324 
   Advanced 1389 1.03 (0.95 - 1.12) 0.436 0.131 
Fatal prostate cancer 936 1.02 (0.92 - 1.12) 0.709 
 Margaric acid (17:0) 
    Total prostate cancer 7036 0.99 (0.96 - 1.02) 0.549 
 Grade 
      Low 3757 0.98 (0.94 - 1.03) 0.442 
   High 726 1.03 (0.93 - 1.13) 0.562 0.130 
Stage 
      Localized 2641 0.96 (0.92 - 1.01) 0.141 
   Advanced 1389 1.06 (0.99 - 1.13) 0.099 0.036 
Fatal prostate cancer 936 0.98 (0.90 - 1.08) 0.738 
 Stearic acid (18:0) 
    Total prostate cancer 7036 0.99 (0.95 - 1.03) 0.628 
 Grade 
      Low 3757 0.96 (0.90 - 1.01) 0.118 
   High 726 1.06 (0.94 - 1.20) 0.349 0.087 
Stage 
      Localized 2641 0.97 (0.90 - 1.04) 0.357 
   Advanced 1389 1.04 (0.95 - 1.14) 0.387 0.117 
Fatal prostate cancer 936 0.99 (0.89 - 1.10) 0.799 
 Arachidic acid (20:0) 
    Total prostate cancer 7036 0.99 (0.94 - 1.04) 0.801 
 Grade 
      Low 3757 0.99 (0.93 - 1.06) 0.861 
   High 726 0.95 (0.81 - 1.12) 0.565 0.963 
Stage 
      Localized 2641 1.01 (0.94 - 1.10) 0.739 
   Advanced 1389 0.96 (0.86 - 1.07) 0.458 0.297 
Fatal prostate cancer 936 0.89 (0.77 - 1.04) 0.140 
 Behenic acid (22:0) 
    Total prostate cancer 7036 0.99 (0.95 - 1.03) 0.616 
 Grade 
      Low 3757 0.99 (0.94 - 1.04) 0.707 
   High 726 0.90 (0.76 - 1.06) 0.210 0.665 
Stage 
      Localized 2641 1.02 (0.95 - 1.09) 0.581 
   Advanced 1389 0.94 (0.85 - 1.04) 0.243 0.275 
Fatal prostate cancer 936 0.90 (0.77 - 1.04) 0.156 
 4:0-10:0 
    Total prostate cancer 7036 1.01 (0.97 - 1.04) 0.718 
 Grade 
      Low 3757 0.98 (0.94 - 1.03) 0.435 
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  High 726 1.06 (0.96 - 1.16) 0.234 0.043 
Stage 
      Localized 2641 0.96 (0.91 - 1.01) 0.093 
   Advanced 1389 1.07 (1.00 - 1.14) 0.054 0.008 
Fatal prostate cancer 936 1.03 (0.95 - 1.12) 0.464 
 12:0-14:0 
    Total prostate cancer 7036 1.00 (0.97 - 1.04) 0.859 
 Grade 
      Low 3757 0.97 (0.93 - 1.02) 0.229 
   High 726 1.07 (0.96 - 1.18) 0.223 0.030 
Stage 
      Localized 2641 0.96 (0.91 - 1.01) 0.124 
   Advanced 1389 1.06 (0.99 - 1.14) 0.103 0.016 
Fatal prostate cancer 936 1.05 (0.96 - 1.16) 0.299 
 Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time 
variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital 
status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, 
moderately active, active, unknown), height (<170, 170–174, 175–179, ≥ 180 cm or unknown), body mass index (<22.5, 
22.5–24.9, 25–29.9, ≥ 30 kg/m2 or unknown), and total energy intake (fifths). 
1 HR (95% CI) estimated per 1-SD increase in fatty acids intake. 
2  Linear trends for HRs estimates over a continuous scale of the individual fatty acid. 
3 P-value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer 
categorized according to prostate tumour grade (low-intermediate or high) and stage (localized or advanced). 
Low-intermediate grade (Gleason score of <8, or grade coded as well, moderately, or poorly differentiated). High grade 
(Gleason score of ≥ 8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0-T2 and N0/Nx and M0, 
or stage coded in the recruitment centre as localized). Advanced stage (T3-T4 and/or N1-N3 and/or M1, and/or stage coded in 
the recruitment centre as metastatic). 
Abbreviation: SFAs saturated fatty acids. 
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Table 3. Multivariable-adjusted hazard ratios (95 % CI) for prostate cancer per 1-SD increase of 
individual monounsaturated fatty acids intake in 142,239 men in EPIC (1992-2013). 
    Calibrated 
  No. cases HR (95 % CI)1 P trend2 P het3 
Total MUFAs 
    Total prostate cancer 7036 0.98 (0.93 - 1.02) 0.303 
 Grade 
      Low 3757 0.95 (0.90 - 1.01) 0.121 
   High 726 1.04 (0.91 - 1.18) 0.613 0.411 
Stage 
      Localized 2641 1.00 (0.93 - 1.08) 0.991 
   Advanced 1389 1.01 (0.91 - 1.11) 0.920 0.942 
Fatal prostate cancer 936 0.98 (0.87 - 1.10) 0.676 
 Palmitoleic acid (16:1n-7c) 
    Total prostate cancer 7036 1.00 (0.94 - 1.05) 0.893 
 Grade 
      Low 3757 0.96 (0.89 - 1.04) 0.353 
   High 726 1.08 (0.91 - 1.28) 0.372 0.317 
Stage 
      Localized 2641 1.01 (0.92 - 1.11) 0.779 
   Advanced 1389 1.02 (0.91 - 1.15) 0.742 0.731 
Fatal prostate cancer 936 1.06 (0.91 - 1.23) 0.446 
 Oleic acid (18:1n-9c) 
    Total prostate cancer 7036 0.98 (0.94 - 1.03) 0.405 
 Grade 
      Low 3757 0.96 (0.90 - 1.02) 0.182 
   High 726 1.03 (0.89 - 1.18) 0.686 0.517 
Stage 
      Localized 2641 0.99 (0.92 - 1.07) 0.847 
   Advanced 1389 1.02 (0.92 - 1.13) 0.777 0.945 
Fatal prostate cancer 936 0.98 (0.87 - 1.11) 0.744 
 Eicosenoic acid (20:1n-9c) 
    Total prostate cancer 7036 1.01 (0.98 - 1.03) 0.540 
 Grade 
      Low 3757 0.98 (0.94 - 1.02) 0.283 
   High 726 1.05 (0.99 - 1.12) 0.094 0.174 
Stage 
      Localized 2641 1.00 (0.95 - 1.04) 0.932 
   Advanced 1389 1.02 (0.97 - 1.06) 0.512 0.550 
Fatal prostate cancer 936 1.05 (1.00 - 1.11) 0.048 
 Erucic acid (22:1n-9c) 
    Total prostate cancer 7036 1.01 (0.98 - 1.03) 0.500 
 Grade 
      Low 3757 0.97 (0.93 - 1.02) 0.262 
   High 726 1.06 (0.99 - 1.12) 0.091 0.129 
Stage 
      Localized 2641 1.00 (0.95 - 1.04) 0.865 
   Advanced 1389 1.02 (0.98 - 1.07) 0.363 0.313 
Fatal prostate cancer 936 1.05 (1.00 - 1.11) 0.055 
 Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time variable), 
educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital status (married, not 
married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, moderately active, active, 
unknown), height (<170, 170–174, 175–179, ≥ 180 cm or unknown), body mass index (<22.5, 22.5–24.9, 25–29.9, ≥ 30 kg/m2 or 
unknown), and total energy intake (fifths). 
1 HR (95% CI) estimated per 1-SD increase in fatty acids intake. 
2  Linear trends for HRs estimates over a continuous scale of the individual fatty acid. 
3 P-value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer categorized 
according to prostate tumour grade (low-intermediate or high) and stage (localized or advanced). 
Low-intermediate grade (Gleason score of <8, or grade coded as well, moderately, or poorly differentiated). High grade (Gleason 
score of ≥ 8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0-T2 and N0/Nx and M0, or stage coded 
in the recruitment centre as localized). Advanced stage (T3-T4 and/or N1-N3 and/or M1, and/or stage coded in the recruitment 
centre as metastatic). 
Abbreviations: MUFAs, monounsaturated fatty acids. 
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Table 4. Multivariable-adjusted hazard ratios (95 % CI) for prostate cancer per 1-SD increase of 
individual polyunsaturated fatty acids intake in 142,239 men in EPIC (1992-2013). 
    Calibrated 
  No. cases HR (95 % CI)1 P trend2 P het3 
Total PUFAs 
    Total prostate cancer 7036 0.98 (0.95 - 1.02) 0.340 
 Grade 
      Low 3757 0.96 (0.91 - 1.01) 0.086 
   High 726 1.00 (0.91 - 1.11) 0.925 0.508 
Stage 
      Localized 2641 0.99 (0.94 - 1.05) 0.830 
   Advanced 1389 0.97 (0.90 - 1.05) 0.434 0.777 
Fatal prostate cancer 936 0.99 (0.90 - 1.09) 0.836 
 Linoleic acid (18:2n-6c) 
    Total prostate cancer 7036 0.98 (0.95 - 1.02) 0.311 
 Grade 
      Low 3757 0.96 (0.91 - 1.00) 0.063 
   High 726 1.01 (0.91 - 1.12) 0.857 0.450 
Stage 
      Localized 2641 0.99 (0.93 - 1.05) 0.678 
   Advanced 1389 0.97 (0.90 - 1.05) 0.440 0.824 
Fatal prostate cancer 936 0.99 (0.90 - 1.08) 0.822 
 α-Linolenic acid (18:3n-3c) 
    Total prostate cancer 7036 0.99 (0.95 - 1.02) 0.502 
 Grade 
      Low 3757 0.97 (0.92 - 1.02) 0.270 
   High 726 1.01 (0.91 - 1.13) 0.817 0.514 
Stage 
      Localized 2641 0.98 (0.92 - 1.05) 0.602 
   Advanced 1389 1.00 (0.93 - 1.08) 0.907 0.434 
Fatal prostate cancer 936 0.99 (0.90 - 1.09) 0.839 
 Arachidonic acid (20:4n-6c) 
    Total prostate cancer 7036 0.99 (0.95 - 1.03) 0.638 
 Grade 
      Low 3757 0.97 (0.92 - 1.03) 0.387 
   High 726 0.94 (0.82 - 1.08) 0.381 0.404 
Stage 
      Localized 2641 1.05 (0.97 - 1.13) 0.213 
   Advanced 1389 0.91 (0.82 - 1.01) 0.072 0.021 
Fatal prostate cancer 936 1.03 (0.92 - 1.15) 0.636 
 Eicosapentaenoic acid (20:5n-3c) 
    Total prostate cancer 7036 1.02 (0.99 - 1.04) 0.272 
 Grade 
      Low 3757 1.01 (0.96 - 1.05) 0.762 
   High 726 0.99 (0.92 - 1.08) 0.895 0.660 
Stage 
      Localized 2641 1.02 (0.98 - 1.07) 0.343 
   Advanced 1389 1.01 (0.95 - 1.07) 0.831 0.601 
Fatal prostate cancer 936 1.07 (1.00 - 1.14) 0.045 
 Docosapentaenoic acid (22:5n-3c) 
   Total prostate cancer 7036 1.00 (0.97 - 1.03) 0.989 
 Grade 
      Low 3757 1.00 (0.96 - 1.04) 0.809 
   High 726 0.97 (0.90 - 1.05) 0.454 0.357 
Stage 
      Localized 2641 1.03 (0.98 - 1.08) 0.251 
   Advanced 1389 1.00 (0.94 - 1.06) 0.914 0.229 
Fatal prostate cancer 936 1.03 (0.97 - 1.10) 0.325 
 Docosahexaenoic acid (22:6n-3c)    
Total prostate cancer 7036 1.01 (0.98 - 1.04) 0.504  
Grade     
  Low 3757 1.00 (0.96 - 1.05) 0.875  
  High 726 0.97 (0.89 - 1.06) 0.523 0.388 
Stage     
  Localized 2641 1.02 (0.97 - 1.07) 0.504  
  Advanced 1389 1.00 (0.94 - 1.07) 0.884 0.479 
Fatal prostate cancer 936 1.06 (0.99 - 1.14) 0.083   
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Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time 
variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital 
status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, 
moderately active, active, unknown), height (<170, 170–174, 175–179, ≥ 180 cm or unknown), body mass index (<22.5, 
22.5–24.9, 25–29.9, ≥ 30 kg/m2 or unknown), and total energy intake (fifths). 
1 HR (95% CI) estimated per 1-SD increase in fatty acids intake. 
2  Linear trends for HRs estimates over a continuous scale of the individual fatty acid. 
3 P-value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer 
categorized according to prostate tumour grade (low-intermediate or high) and stage (localized or advanced). 
Low-intermediate grade (Gleason score of <8, or grade coded as well, moderately, or poorly differentiated). High grade 
(Gleason score of ≥ 8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0-T2 and N0/Nx and 
M0, or stage coded in the recruitment centre as localized). Advanced stage (T3-T4 and/or N1-N3 and/or M1, and/or stage 
coded in the recruitment centre as metastatic). 
Abbreviation: PUFAs, polyunsaturated fatty acids. 
 
 
